News | April 19, 2010

Merge Puts a Price on $200 Million Aggregate Principal

April 19, 2010 - Merge Healthcare Inc. (Merge) today announced the pricing of its $200 million aggregate principal amount of 11.75 percent senior secured notes due 2015. The issue price is 97.266 percent of the principal amount of the notes.

The notes were offered in a private placement pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended. The sale of the notes is expected to close on or about April 28, 2010. The notes will be senior obligations of Merge and will be guaranteed on a senior basis by all of Merge’s domestic restricted subsidiaries.

For more information: www.merge.com

Related Content

The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | Artificial Intelligence | June 15, 2021
June 15, 2021 — The impact of deploying ...
Cina Chest is part of Avicenna’s CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-Marked solution that supports the detection and triage of stroke and neurovascular emergencies.
News | Artificial Intelligence | June 03, 2021
June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced
International medical imaging IT and cybersecurity company Sectra will install its solution for digital pathology at Institut Curie, one of the most recognized and prestigious cancer centers in France.
News | Enterprise Imaging | May 24, 2021
May 24, 2021 — International medical imaging IT and cybersecurity company ...
The Healthcare Information and Management Systems Society, Inc. (HIMSS) 2021 Conference, scheduled for August 9-13 in Las Vegas, will be one of the first to take a step back to normalcy

Getty Images

News | HIMSS | May 17, 2021
May 17, 2021 — It looks like in-person conferences are making a comeback.
Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address

Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address inherent biases in healthcare algorithms and their deployment. Image courtesy of Regenstrief Institute

News | Artificial Intelligence | May 14, 2021
May 14, 2021 — Artificial intelligence